For years, Brazil has depended heavily on imported blockbuster medicines developed by multinational pharmaceutical companies. That may be about to change. Following the expiration of the Brazilian patent for semaglutide—the active ingredient in Novo Nordisk’s Ozempic—a race has begun among domestic pharmaceutical companies to produce more affordable alternatives.

The development is about much more than weight-loss drugs. It illustrates how patent expirations can reshape entire industries, create new business opportunities for domestic manufacturers, and expand access to medicines for millions of patients.

A Billion-Dollar Market Opens Up

Few pharmaceutical products have generated as much attention as GLP-1 medications such as Ozempic and Mounjaro. Originally developed to treat Type 2 diabetes, these drugs have also proven remarkably effective in helping patients lose weight, fueling global demand that has often outpaced production.

Brazil is no exception. Industry estimates suggest that semaglutide products generate at least R$5 billion (approximately US$1 billion) in annual sales in Brazil alone. The actual market is likely even larger, as official figures exclude compounded products prepared by pharmacies and medications entering the country through informal channels.

With demand continuing to grow, the expiration of semaglutide’s Brazilian patent in March 2026 has opened the door for domestic manufacturers eager to enter one of the fastest-growing pharmaceutical markets in the country.

Brazilian Companies Move Quickly

Hypera, one of Brazil’s largest pharmaceutical companies, recently filed its injectable semaglutide pen, marketed under the name Semavy, as it moves toward commercial approval. Another Brazilian pharmaceutical company, EMS, has already received regulatory approval for its competing product, Ozivy, which has begun reaching pharmacies.

Novo Nordisk is not standing still. The Danish pharmaceutical giant has partnered with Brazilian drugmaker Eurofarma to manufacture semaglutide locally, allowing it to remain competitive as domestic rivals enter the market.

The result is a level of competition that Brazilian patients have rarely seen for a high-profile biologic medicine.

Competition Could Finally Lower Prices

One of the biggest criticisms surrounding GLP-1 medications has been their price. For many patients, these treatments remain prohibitively expensive despite their proven effectiveness.

As additional manufacturers enter the market, competition is expected to put downward pressure on prices. Lower prices could expand access for private patients while also increasing the likelihood that semaglutide-based therapies eventually become available through Brazil’s public healthcare system, the SUS.

For millions of Brazilians living with obesity or Type 2 diabetes, that could represent a significant improvement in treatment options.

More Than Just a Generic Drug

Interestingly, Brazil’s regulatory framework treats these products differently from traditional generic medicines.

Because injectable biologic products such as semaglutide are considerably more complex than conventional tablets, Brazilian regulations require domestic versions to undergo their own approval process rather than simply being classified as generics.

That means local manufacturers must demonstrate consistent quality, safety, and manufacturing capability before entering the market. Producing these sophisticated injectable drugs is considerably more challenging than manufacturing conventional pills.

A Win for Brazil’s Pharmaceutical Industry

The emergence of locally developed semaglutide products also reflects the growing maturity of Brazil’s pharmaceutical sector.

Companies such as Hypera, EMS, Eurofarma, and others have steadily expanded their manufacturing capabilities over the past decade. Instead of relying exclusively on imported medicines, Brazil is increasingly building domestic capacity to produce complex pharmaceutical products.

This trend supports not only healthcare affordability but also industrial development, skilled employment, and greater resilience against global supply disruptions.

The Bigger Picture

Brazil’s semaglutide market reflects a broader global trend. As patents expire on some of the world’s most profitable medicines, pharmaceutical companies across emerging markets are preparing to manufacture their own versions.

This process has transformed industries before. Generic medicines dramatically reduced the cost of many life-saving drugs over the past three decades. While biologic medicines are more technically demanding, they may be following a similar path as manufacturing capabilities improve.

The result is likely to be increased competition, lower prices, and wider access for patients—while also reshaping the competitive landscape for multinational pharmaceutical companies.

The race to produce semaglutide in Brazil is about far more than weight-loss injections. It demonstrates how innovation, patent law, industrial policy, and healthcare economics intersect.

For Brazilian pharmaceutical companies, the opportunity is enormous. For multinational drugmakers, the era of uncontested dominance may be coming to an end. And for patients, increased competition offers the prospect of something that has long been missing from one of healthcare’s fastest-growing markets: affordable access.

Können Sie es sich leisten, nicht in den brasilianischen Markt einzutreten? Sprechen Sie mit uns, wir machen Ihren Erfolg in Brasilien möglich.